Solventum (NYSE:SOLV) Coverage Initiated at Wolfe Research

Wolfe Research began coverage on shares of Solventum (NYSE:SOLV) in a report released on Thursday, MarketBeat Ratings reports. The brokerage issued a peer perform rating on the stock.

Other research analysts have also recently issued reports about the company. Wells Fargo & Company decreased their target price on Solventum from $69.00 to $64.00 and set an equal weight rating for the company in a research note on Friday, August 9th. Argus assumed coverage on Solventum in a research note on Monday, June 24th. They issued a hold rating for the company. BTIG Research began coverage on Solventum in a research note on Thursday, September 5th. They issued a neutral rating for the company. Bank of America reduced their price objective on Solventum from $70.00 to $60.00 and set a neutral rating for the company in a research report on Tuesday, June 25th. Finally, The Goldman Sachs Group upped their price objective on Solventum from $48.00 to $54.00 and gave the stock a sell rating in a research report on Monday, August 12th. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Hold and an average price target of $58.25.

Solventum Stock Down 0.8 %

Shares of Solventum stock opened at $67.57 on Thursday. The company has a quick ratio of 0.96, a current ratio of 1.31 and a debt-to-equity ratio of 2.90. Solventum has a 12 month low of $47.16 and a 12 month high of $96.05. The business’s fifty day moving average is $62.70.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Thursday, August 8th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.10. The company had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.05 billion. The firm’s revenue was up .2% compared to the same quarter last year. As a group, equities research analysts expect that Solventum will post 6.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Solventum

A number of large investors have recently added to or reduced their stakes in the stock. Deseret Mutual Benefit Administrators acquired a new stake in shares of Solventum in the 2nd quarter valued at $25,000. Hollencrest Capital Management acquired a new stake in shares of Solventum in the 2nd quarter valued at $25,000. Partnership Wealth Management LLC acquired a new stake in shares of Solventum in the 2nd quarter valued at $26,000. Richard W. Paul & Associates LLC acquired a new stake in shares of Solventum in the 2nd quarter valued at $26,000. Finally, Family Firm Inc. acquired a new stake in shares of Solventum in the 2nd quarter valued at $26,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.